meglumine ginkgolide B

Meglumine ginkgolide B is a pharmaceutical formulation consisting of the meglumine salt of ginkgolide B, a terpene lactone isolated from the leaves of the *Ginkgo biloba* tree. It functions as a potent and selective antagonist of the platelet-activating factor (PAF) receptor. By blocking the binding of PAF to its receptor, the drug inhibits PAF-induced platelet aggregation, leukocyte activation, and the release of inflammatory mediators. It is primarily being developed by Jiangsu Ke Feiping Pharmaceutical for the treatment of acute ischemic stroke, where it aims to reduce neuroinflammation and secondary brain injury following a stroke event. The meglumine salt form is utilized to enhance the aqueous solubility of the hydrophobic ginkgolide B molecule, facilitating its administration as an intravenous injection.

Other names

ginkgolide B megluminemeglumine ginkgolide B injection